USANA Health Sciences Inc. - 10-Q Filing Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for USANA Health Sciences, Inc., a direct selling company developing and distributing nutritional and personal care products. The reporting period covers the quarter and nine months ended September 29, 2007. The company operates in one reportable segment (Direct Selling) across North America and the Asia Pacific region. As of the period end, the company had approximately 180,000 active Associates and 79,000 active Preferred Customers.
Key Financial Metrics
| Metric (in thousands) | Q3 2007 | Q3 2006 | 9M 2007 | 9M 2006 |
|---|---|---|---|---|
| Net Sales | $106,181 | $91,967 | $314,401 | $267,045 |
| Gross Profit | $84,221 | $71,693 | $249,412 | $209,074 |
| Gross Margin | 79.3% | 78.0% | 79.3% | 78.3% |
| Net Earnings | $11,258 | $10,223 | $34,258 | $30,127 |
| Diluted EPS (Continuing Ops) | $0.70 | $0.56 | $2.00 | $1.63 |
| Cash and Equivalents | $11,718 | $27,029 (Dec 2006) | $11,718 | $27,029 (Dec 2006) |
| Operating Cash Flow (9M) | $44,142 | $45,039 | $44,142 | $45,039 |
| Line of Credit Outstanding | $34,625 | $0 | $34,625 | $0 |
Note: Prior period figures have been revised to comply with EITF 01-09 regarding Associate incentives, reducing reported net sales by 1.6% for Q3 2006.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15.5% in Q3 and 17.7% for the nine months ended September 29, 2007, compared to the prior year. Growth was driven by a 24.1% increase in active Associates (to 180,000) and the launch of operations in Malaysia, which contributed $4.9 million in Q3 sales.
- Profitability: Income from continuing operations rose 11.7% in Q3 and 13.4% for the nine-month period. Gross margins improved due to production efficiencies, lower freight costs, and a one-time benefit from the sale of the third-party contract manufacturing business.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses increased to 21.7% of sales in Q3 (from 19.4% in 2006). This was driven by international expansion, wage increases, equity-based compensation, and approximately $700,000 in legal fees related to defending against third-party allegations.
- Liquidity and Debt: Cash and cash equivalents decreased from $27.0 million to $11.7 million. The company utilized a $40 million line of credit, with $34.6 million outstanding as of September 29, 2007, primarily to fund facility expansions in Utah and Australia and aggressive share repurchases ($79.6 million in the first nine months).
- Discontinued Operations: The company completed the sale of its third-party contract manufacturing assets in August 2007. Results for this segment are now classified as discontinued operations.
Guidance, Outlook, and Risks
- Outlook: Management expects gross profit margins in Q4 2007 to approximate Q3 levels. SG&A expenses as a percentage of sales are also expected to remain at Q3 levels. The effective tax rate for the full year 2007 is projected at 35.5%.
- Capital Projects: The company is expanding its corporate headquarters in Salt Lake City (total investment estimated at $21 million) and a new facility in Sydney, Australia (total investment estimated at $14 million).
- Legal Contingencies: The company is facing multiple lawsuits, including three consolidated shareholder class actions, a shareholder derivative suit, and a class action by former Associates. These were prompted by allegations from a third-party detractor (Barry Minkow). The company believes the claims are without merit but notes potential losses are not estimable. An informal inquiry by the SEC is also ongoing.
- Risk Factors: Key risks include dependence on the network marketing model, high Associate turnover, regulatory scrutiny (FDA/FTC), foreign currency fluctuations, and the outcome of pending litigation.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with the credit agreement covenants (EBITDA and debt coverage ratios), especially given the high utilization of the line of credit ($34.6M of $40M).
- Legal Exposure: Monitor the status of the consolidated shareholder class actions and the SEC informal inquiry, as these could result in significant financial or reputational damage.
- Share Repurchase Impact: Assess the sustainability of the aggressive share buyback program ($79.6M in 9 months) given the reduction in cash reserves and increased debt.
- Associate Growth Quality: Evaluate the retention rates of the 35,000 new Associates added in the period to ensure sales growth is sustainable and not driven by short-term promotions.
- Regulatory Compliance: Confirm adherence to new FDA Good Manufacturing Practice (GMP) regulations effective June 2008 and the Dietary Supplement & Nonprescription Drug Consumer Protection Act.